nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0747	0.155	CbGbCtD
Irbesartan—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0622	0.129	CbGbCtD
Irbesartan—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0545	0.113	CbGbCtD
Irbesartan—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0521	0.108	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0497	0.103	CbGbCtD
Irbesartan—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0326	0.0674	CbGbCtD
Irbesartan—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0314	0.0651	CbGbCtD
Irbesartan—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0303	0.0627	CbGbCtD
Irbesartan—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0243	0.0504	CbGbCtD
Irbesartan—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0223	0.0462	CbGbCtD
Irbesartan—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0139	0.0288	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.0137	0.0283	CbGbCtD
Irbesartan—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0127	0.0264	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0087	0.018	CbGbCtD
Irbesartan—Candesartan—ABCB1—peripheral nervous system neoplasm	0.00037	0.608	CrCbGaD
Irbesartan—Losartan—ABCB1—peripheral nervous system neoplasm	0.000239	0.392	CrCbGaD
Irbesartan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000159	0.000426	CcSEcCtD
Irbesartan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000159	0.000425	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000425	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000159	0.000425	CcSEcCtD
Irbesartan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000157	0.000421	CcSEcCtD
Irbesartan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000157	0.000421	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00042	CcSEcCtD
Irbesartan—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000416	CcSEcCtD
Irbesartan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000155	0.000414	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000414	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000413	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000411	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000411	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000411	CcSEcCtD
Irbesartan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000153	0.00041	CcSEcCtD
Irbesartan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000153	0.000409	CcSEcCtD
Irbesartan—JUN—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	0.000152	0.00107	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—AKT1—peripheral nervous system neoplasm	0.000152	0.00107	CbGpPWpGaD
Irbesartan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000406	CcSEcCtD
Irbesartan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000152	0.000405	CcSEcCtD
Irbesartan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000151	0.000405	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—peripheral nervous system neoplasm	0.000151	0.00106	CbGpPWpGaD
Irbesartan—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000404	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000151	0.00106	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—ERBB2—peripheral nervous system neoplasm	0.000151	0.00106	CbGpPWpGaD
Irbesartan—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000403	CcSEcCtD
Irbesartan—JUN—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.00015	0.00106	CbGpPWpGaD
Irbesartan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00015	0.000402	CcSEcCtD
Irbesartan—JUN—BCR signaling pathway—AKT1—peripheral nervous system neoplasm	0.00015	0.00106	CbGpPWpGaD
Irbesartan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000401	CcSEcCtD
Irbesartan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00015	0.000401	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000401	CcSEcCtD
Irbesartan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000149	0.000399	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000399	CcSEcCtD
Irbesartan—JUN—Apoptosis—TP53—peripheral nervous system neoplasm	0.000148	0.00104	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	0.000148	0.00104	CbGpPWpGaD
Irbesartan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000148	0.000396	CcSEcCtD
Irbesartan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000148	0.000395	CcSEcCtD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—peripheral nervous system neoplasm	0.000148	0.00104	CbGpPWpGaD
Irbesartan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000147	0.000393	CcSEcCtD
Irbesartan—JUN—Signaling by NOTCH—MYC—peripheral nervous system neoplasm	0.000147	0.00103	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—MYC—peripheral nervous system neoplasm	0.000147	0.00103	CbGpPWpGaD
Irbesartan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000146	0.000392	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000389	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000145	0.000389	CcSEcCtD
Irbesartan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000145	0.000389	CcSEcCtD
Irbesartan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000145	0.000389	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000145	0.00102	CbGpPWpGaD
Irbesartan—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000386	CcSEcCtD
Irbesartan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000144	0.000386	CcSEcCtD
Irbesartan—Pain—Etoposide—peripheral nervous system neoplasm	0.000144	0.000386	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000385	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000385	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000384	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000382	CcSEcCtD
Irbesartan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000143	0.000382	CcSEcCtD
Irbesartan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000142	0.000381	CcSEcCtD
Irbesartan—JUN—Immune System—CD55—peripheral nervous system neoplasm	0.000141	0.000992	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—CDKN2A—peripheral nervous system neoplasm	0.000141	0.000992	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNS—peripheral nervous system neoplasm	0.000141	0.000992	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—NRAS—peripheral nervous system neoplasm	0.000141	0.000992	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000141	0.000991	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—ERBB2—peripheral nervous system neoplasm	0.00014	0.000987	CbGpPWpGaD
Irbesartan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000375	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000375	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000374	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000374	CcSEcCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—peripheral nervous system neoplasm	0.000139	0.000978	CbGpPWpGaD
Irbesartan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000139	0.000371	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000371	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000138	0.00037	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000138	0.00037	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.000369	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000138	0.000369	CcSEcCtD
Irbesartan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000138	0.000368	CcSEcCtD
Irbesartan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000137	0.000367	CcSEcCtD
Irbesartan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.000364	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000136	0.000956	CbGpPWpGaD
Irbesartan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.000364	CcSEcCtD
Irbesartan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000136	0.000363	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000362	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—NME1—peripheral nervous system neoplasm	0.000135	0.000951	CbGpPWpGaD
Irbesartan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000135	0.000362	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.00036	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000134	0.000944	CbGpPWpGaD
Irbesartan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000134	0.000358	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000357	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000357	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000133	0.000356	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000133	0.000356	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000356	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000356	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000356	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—CASP3—peripheral nervous system neoplasm	0.000133	0.000934	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—ERBB2—peripheral nervous system neoplasm	0.000133	0.000933	CbGpPWpGaD
Irbesartan—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000354	CcSEcCtD
Irbesartan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000132	0.000354	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000132	0.000929	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000132	0.000927	CbGpPWpGaD
Irbesartan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000132	0.000353	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000353	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—MYC—peripheral nervous system neoplasm	0.000131	0.000924	CbGpPWpGaD
Irbesartan—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000351	CcSEcCtD
Irbesartan—Rash—Vincristine—peripheral nervous system neoplasm	0.000131	0.000351	CcSEcCtD
Irbesartan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000131	0.000351	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000131	0.00035	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000131	0.00035	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000349	CcSEcCtD
Irbesartan—Headache—Vincristine—peripheral nervous system neoplasm	0.00013	0.000349	CcSEcCtD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—peripheral nervous system neoplasm	0.00013	0.000916	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—COX2—peripheral nervous system neoplasm	0.00013	0.000915	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00013	0.000912	CbGpPWpGaD
Irbesartan—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000347	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000346	CcSEcCtD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000129	0.000907	CbGpPWpGaD
Irbesartan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.000343	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000343	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000342	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	0.000128	0.000898	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000127	0.000896	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—peripheral nervous system neoplasm	0.000127	0.000893	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000127	0.000889	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000126	0.000885	CbGpPWpGaD
Irbesartan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000126	0.000337	CcSEcCtD
Irbesartan—JUN—Apoptosis—AKT1—peripheral nervous system neoplasm	0.000125	0.000881	CbGpPWpGaD
Irbesartan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000335	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000124	0.000332	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000124	0.000872	CbGpPWpGaD
Irbesartan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000332	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000124	0.000868	CbGpPWpGaD
Irbesartan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000124	0.000331	CcSEcCtD
Irbesartan—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00033	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00033	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.00033	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000123	0.000865	CbGpPWpGaD
Irbesartan—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000329	CcSEcCtD
Irbesartan—JUN—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000123	0.000862	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000122	0.00086	CbGpPWpGaD
Irbesartan—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000327	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000122	0.000859	CbGpPWpGaD
Irbesartan—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000327	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000325	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000324	CcSEcCtD
Irbesartan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000121	0.000323	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000323	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000323	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000323	CcSEcCtD
Irbesartan—JUN—Signaling by NOTCH—TP53—peripheral nervous system neoplasm	0.00012	0.000847	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—peripheral nervous system neoplasm	0.00012	0.000847	CbGpPWpGaD
Irbesartan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000321	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.00012	0.000843	CbGpPWpGaD
Irbesartan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000321	CcSEcCtD
Irbesartan—JUN—Androgen receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.00012	0.000841	CbGpPWpGaD
Irbesartan—Chills—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000319	CcSEcCtD
Irbesartan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000119	0.000319	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000119	0.000836	CbGpPWpGaD
Irbesartan—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000318	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	0.000119	0.000834	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—HRAS—peripheral nervous system neoplasm	0.000119	0.000834	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000119	0.000833	CbGpPWpGaD
Irbesartan—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000317	CcSEcCtD
Irbesartan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000313	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000117	0.000819	CbGpPWpGaD
Irbesartan—Rash—Cisplatin—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Irbesartan—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000116	0.00031	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000115	0.000308	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—HRAS—peripheral nervous system neoplasm	0.000115	0.00081	CbGpPWpGaD
Irbesartan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000307	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000305	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000305	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000114	0.000802	CbGpPWpGaD
Irbesartan—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000305	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000114	0.000798	CbGpPWpGaD
Irbesartan—Tension—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000304	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000303	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000113	0.000794	CbGpPWpGaD
Irbesartan—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000301	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—peripheral nervous system neoplasm	0.000112	0.000789	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000112	0.000785	CbGpPWpGaD
Irbesartan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000299	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—NRAS—peripheral nervous system neoplasm	0.000111	0.000783	CbGpPWpGaD
Irbesartan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000111	0.000298	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000298	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000297	CcSEcCtD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000111	0.00078	CbGpPWpGaD
Irbesartan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000297	CcSEcCtD
Irbesartan—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000295	CcSEcCtD
Irbesartan—PTGS1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00011	0.000773	CbGpPWpGaD
Irbesartan—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000294	CcSEcCtD
Irbesartan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000109	0.000292	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000292	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000108	0.000759	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000287	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000107	0.000754	CbGpPWpGaD
Irbesartan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000107	0.000287	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000286	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000286	CcSEcCtD
Irbesartan—JUN—Immune System—CD34—peripheral nervous system neoplasm	0.000107	0.000752	CbGpPWpGaD
Irbesartan—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000286	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	0.000107	0.000751	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000107	0.00075	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000107	0.00075	CbGpPWpGaD
Irbesartan—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000285	CcSEcCtD
Irbesartan—Rash—Etoposide—peripheral nervous system neoplasm	0.000106	0.000284	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000106	0.000284	CcSEcCtD
Irbesartan—Headache—Etoposide—peripheral nervous system neoplasm	0.000106	0.000282	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000282	CcSEcCtD
Irbesartan—CYP2C8—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000105	0.000739	CbGpPWpGaD
Irbesartan—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000281	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000281	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	0.000105	0.000737	CbGpPWpGaD
Irbesartan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000279	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000278	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000278	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000104	0.000729	CbGpPWpGaD
Irbesartan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000278	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000277	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000103	0.000726	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	0.000103	0.000726	CbGpPWpGaD
Irbesartan—JUN—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000103	0.000724	CbGpPWpGaD
Irbesartan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000275	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—AKT1—peripheral nervous system neoplasm	0.000102	0.000715	CbGpPWpGaD
Irbesartan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000272	CcSEcCtD
Irbesartan—Cough—Epirubicin—peripheral nervous system neoplasm	0.000101	0.00027	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.00027	CcSEcCtD
Irbesartan—Nausea—Etoposide—peripheral nervous system neoplasm	0.0001	0.000268	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—peripheral nervous system neoplasm	9.99e-05	0.000267	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	9.94e-05	0.000266	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000265	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—TP53—peripheral nervous system neoplasm	9.86e-05	0.000693	CbGpPWpGaD
Irbesartan—Chest pain—Epirubicin—peripheral nervous system neoplasm	9.85e-05	0.000264	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—peripheral nervous system neoplasm	9.85e-05	0.000264	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	9.85e-05	0.000264	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	9.85e-05	0.000692	CbGpPWpGaD
Irbesartan—Agitation—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000263	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—peripheral nervous system neoplasm	9.82e-05	0.000263	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	9.79e-05	0.000262	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—peripheral nervous system neoplasm	9.74e-05	0.00026	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.7e-05	0.000681	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.66e-05	0.000679	CbGpPWpGaD
Irbesartan—Malaise—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000258	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	9.64e-05	0.000258	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	9.62e-05	0.000257	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—peripheral nervous system neoplasm	9.6e-05	0.000257	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	9.59e-05	0.000256	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.52e-05	0.000669	CbGpPWpGaD
Irbesartan—Oedema—Epirubicin—peripheral nervous system neoplasm	9.45e-05	0.000253	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	9.45e-05	0.000253	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.000252	CcSEcCtD
Irbesartan—Infection—Epirubicin—peripheral nervous system neoplasm	9.38e-05	0.000251	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.37e-05	0.000658	CbGpPWpGaD
Irbesartan—Cough—Doxorubicin—peripheral nervous system neoplasm	9.34e-05	0.00025	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.34e-05	0.000656	CbGpPWpGaD
Irbesartan—Shock—Epirubicin—peripheral nervous system neoplasm	9.29e-05	0.000249	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	9.28e-05	0.000652	CbGpPWpGaD
Irbesartan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	9.26e-05	0.000248	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	9.25e-05	0.000247	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000247	CcSEcCtD
Irbesartan—JUN—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	9.22e-05	0.000648	CbGpPWpGaD
Irbesartan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	9.22e-05	0.000247	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	9.17e-05	0.000245	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	9.17e-05	0.000645	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	9.14e-05	0.000642	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	9.13e-05	0.000244	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.13e-05	0.000642	CbGpPWpGaD
Irbesartan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000244	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000244	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000244	CcSEcCtD
Irbesartan—JUN—Immune System—NCAM1—peripheral nervous system neoplasm	9.1e-05	0.000639	CbGpPWpGaD
Irbesartan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	9.09e-05	0.000243	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.000242	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	9.01e-05	0.000241	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—peripheral nervous system neoplasm	9e-05	0.000241	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	8.96e-05	0.000629	CbGpPWpGaD
Irbesartan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	0.000239	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.92e-05	0.000627	CbGpPWpGaD
Irbesartan—Hypotension—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000236	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000234	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000234	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	8.73e-05	0.000613	CbGpPWpGaD
Irbesartan—Infection—Doxorubicin—peripheral nervous system neoplasm	8.68e-05	0.000232	CcSEcCtD
Irbesartan—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.63e-05	0.000607	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	8.61e-05	0.00023	CcSEcCtD
Irbesartan—Shock—Doxorubicin—peripheral nervous system neoplasm	8.6e-05	0.00023	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000229	CcSEcCtD
Irbesartan—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.56e-05	0.000601	CbGpPWpGaD
Irbesartan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	8.56e-05	0.000229	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—ENO2—peripheral nervous system neoplasm	8.55e-05	0.000601	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.53e-05	0.0006	CbGpPWpGaD
Irbesartan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000228	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	8.52e-05	0.000599	CbGpPWpGaD
Irbesartan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	8.49e-05	0.000227	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	8.48e-05	0.000227	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.48e-05	0.000596	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—peripheral nervous system neoplasm	8.48e-05	0.000596	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000226	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	8.42e-05	0.000225	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—peripheral nervous system neoplasm	8.4e-05	0.000225	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	8.39e-05	0.00059	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	8.38e-05	0.000589	CbGpPWpGaD
Irbesartan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	8.33e-05	0.000223	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	8.31e-05	0.000222	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	8.21e-05	0.00022	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000218	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	8.15e-05	0.000218	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—peripheral nervous system neoplasm	8.14e-05	0.000218	CcSEcCtD
Irbesartan—JUN—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	8.14e-05	0.000572	CbGpPWpGaD
Irbesartan—Pain—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000216	CcSEcCtD
Irbesartan—Constipation—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000216	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	7.96e-05	0.000213	CcSEcCtD
Irbesartan—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	7.95e-05	0.000559	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—peripheral nervous system neoplasm	7.86e-05	0.000552	CbGpPWpGaD
Irbesartan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	7.85e-05	0.00021	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	7.84e-05	0.000551	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	7.82e-05	0.000549	CbGpPWpGaD
Irbesartan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	7.79e-05	0.000208	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	7.78e-05	0.000208	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000208	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000207	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	7.69e-05	0.000206	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.69e-05	0.000541	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	7.62e-05	0.000536	CbGpPWpGaD
Irbesartan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.6e-05	0.000203	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.55e-05	0.000202	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	7.54e-05	0.000202	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.51e-05	0.000528	CbGpPWpGaD
Irbesartan—Urticaria—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.000201	CcSEcCtD
Irbesartan—JUN—Insulin Signaling—AKT1—peripheral nervous system neoplasm	7.48e-05	0.000526	CbGpPWpGaD
Irbesartan—Pain—Doxorubicin—peripheral nervous system neoplasm	7.47e-05	0.0002	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—peripheral nervous system neoplasm	7.47e-05	0.0002	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	7.47e-05	0.0002	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	7.47e-05	0.0002	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.41e-05	0.000521	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—peripheral nervous system neoplasm	7.39e-05	0.000519	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	7.38e-05	0.000519	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	7.34e-05	0.000516	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.31e-05	0.000514	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.3e-05	0.000513	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—BCHE—peripheral nervous system neoplasm	7.23e-05	0.000508	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.22e-05	0.000507	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	7.21e-05	0.000506	CbGpPWpGaD
Irbesartan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	7.2e-05	0.000193	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.2e-05	0.000506	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	7.15e-05	0.000191	CcSEcCtD
Irbesartan—JUN—Immune System—IFNB1—peripheral nervous system neoplasm	7.14e-05	0.000502	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.1e-05	0.000499	CbGpPWpGaD
Irbesartan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	6.96e-05	0.000186	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.96e-05	0.000489	CbGpPWpGaD
Irbesartan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000186	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	6.91e-05	0.000185	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	6.91e-05	0.000185	CcSEcCtD
Irbesartan—JUN—Innate Immune System—PTPN11—peripheral nervous system neoplasm	6.91e-05	0.000485	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	6.9e-05	0.000485	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.89e-05	0.000484	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TH—peripheral nervous system neoplasm	6.79e-05	0.000477	CbGpPWpGaD
Irbesartan—Asthenia—Epirubicin—peripheral nervous system neoplasm	6.78e-05	0.000181	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.7e-05	0.000471	CbGpPWpGaD
Irbesartan—Pruritus—Epirubicin—peripheral nervous system neoplasm	6.68e-05	0.000179	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.66e-05	0.000468	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—peripheral nervous system neoplasm	6.52e-05	0.000458	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.5e-05	0.000456	CbGpPWpGaD
Irbesartan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.46e-05	0.000173	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.44e-05	0.000172	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.38e-05	0.000449	CbGpPWpGaD
Irbesartan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	6.27e-05	0.000168	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—peripheral nervous system neoplasm	6.25e-05	0.000167	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	6.18e-05	0.000165	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000161	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.00016	CcSEcCtD
Irbesartan—Rash—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.000159	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.000159	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—TP53—peripheral nervous system neoplasm	5.94e-05	0.000417	CbGpPWpGaD
Irbesartan—Headache—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000158	CcSEcCtD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.9e-05	0.000415	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.89e-05	0.000414	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.83e-05	0.00041	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.78e-05	0.000406	CbGpPWpGaD
Irbesartan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	5.78e-05	0.000155	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.73e-05	0.000403	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.65e-05	0.000397	CbGpPWpGaD
Irbesartan—Nausea—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.00015	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000149	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—GNAS—peripheral nervous system neoplasm	5.55e-05	0.00039	CbGpPWpGaD
Irbesartan—JUN—Immune System—HGF—peripheral nervous system neoplasm	5.51e-05	0.000387	CbGpPWpGaD
Irbesartan—Rash—Doxorubicin—peripheral nervous system neoplasm	5.51e-05	0.000147	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.51e-05	0.000147	CcSEcCtD
Irbesartan—Headache—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000146	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.46e-05	0.000384	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ERBB2—peripheral nervous system neoplasm	5.46e-05	0.000384	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ABCB1—peripheral nervous system neoplasm	5.44e-05	0.000382	CbGpPWpGaD
Irbesartan—Nausea—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000139	CcSEcCtD
Irbesartan—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	5.14e-05	0.000361	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.01e-05	0.000352	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5e-05	0.000352	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.94e-05	0.000347	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	4.92e-05	0.000346	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	4.82e-05	0.000339	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.8e-05	0.000338	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	4.74e-05	0.000333	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.52e-05	0.000317	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.44e-05	0.000312	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.28e-05	0.000301	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	4.22e-05	0.000296	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	4.18e-05	0.000294	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—peripheral nervous system neoplasm	4.15e-05	0.000292	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.11e-05	0.000289	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.08e-05	0.000287	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	4.07e-05	0.000286	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	4.04e-05	0.000284	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTPN11—peripheral nervous system neoplasm	4.02e-05	0.000283	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	4.01e-05	0.000282	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	3.89e-05	0.000273	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.88e-05	0.000273	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	3.86e-05	0.000271	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	3.83e-05	0.000269	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.81e-05	0.000268	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.74e-05	0.000263	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.57e-05	0.000251	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.54e-05	0.000249	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.51e-05	0.000246	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.48e-05	0.000245	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.42e-05	0.000241	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.3e-05	0.000232	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.3e-05	0.000232	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.21e-05	0.000226	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.18e-05	0.000224	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—peripheral nervous system neoplasm	3.18e-05	0.000223	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	3.12e-05	0.00022	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	3.11e-05	0.000219	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	3.07e-05	0.000215	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.04e-05	0.000213	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.92e-05	0.000205	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.76e-05	0.000194	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.75e-05	0.000193	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.68e-05	0.000188	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.67e-05	0.000187	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.64e-05	0.000186	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	2.63e-05	0.000185	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.6e-05	0.000183	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.59e-05	0.000182	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	2.55e-05	0.00018	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.54e-05	0.000179	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.53e-05	0.000178	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.52e-05	0.000177	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.51e-05	0.000176	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.5e-05	0.000175	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.48e-05	0.000175	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	2.47e-05	0.000174	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—peripheral nervous system neoplasm	2.42e-05	0.00017	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.29e-05	0.000161	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.16e-05	0.000152	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	2.16e-05	0.000152	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	2.14e-05	0.00015	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.09e-05	0.000147	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.06e-05	0.000145	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.06e-05	0.000144	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.04e-05	0.000143	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.04e-05	0.000143	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	2.03e-05	0.000143	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	2.02e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	2.01e-05	0.000141	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	1.98e-05	0.000139	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.95e-05	0.000137	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.95e-05	0.000137	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.87e-05	0.000131	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.83e-05	0.000128	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—peripheral nervous system neoplasm	1.77e-05	0.000124	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.74e-05	0.000123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.72e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.67e-05	0.000117	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.64e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.63e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.61e-05	0.000113	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.6e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.56e-05	0.00011	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—peripheral nervous system neoplasm	1.56e-05	0.00011	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.53e-05	0.000108	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—peripheral nervous system neoplasm	1.5e-05	0.000105	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.46e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.41e-05	9.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.4e-05	9.86e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.38e-05	9.68e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.35e-05	9.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.35e-05	9.46e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.33e-05	9.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.2e-05	8.41e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.14e-05	8.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.08e-05	7.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.06e-05	7.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.01e-05	7.1e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	8.43e-06	5.93e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	5.45e-06	3.83e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	4.47e-06	3.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	4.43e-06	3.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.79e-06	2.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.92e-06	2.05e-05	CbGpPWpGaD
